-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$37.8366.65% Upside
Recent Analyst Forecasts and Stock Ratings
Viridian Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Viridian Therapeutics, Inc.?
Viridian Therapeutics, Inc. has been rated by research analysts at RBC Capital, Needham, B.Riley Financial, Stifel Nicolaus, BTIG, Goldman Sachs in the past 90 days.